Trial · NCT02864953
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Part 1: Percentage of Participants With Improvement in Functional Outcome at Day 90 Assessed Via the Modified Rankin Scale (mRS) | Placebo | Score: 0/1 | 1.4 | percentage of participants | |
| Part 1: Percentage of Participants With Improvement in Functional Outcome at Day 90 Assessed Via the Modified Rankin Scale (mRS) | BIIB093 | Score: 0/1 | 3.2 | percentage of participants | |
| Part 1: Percentage of Participants With Improvement in Functional Outcome at Day 90 Assessed Via the Modified Rankin Scale (mRS) | Placebo | Score: 2 | 2.8 | percentage of participants | |
| Part 1: Percentage of Participants With Improvement in Functional Outcome at Day 90 Assessed Via the Modified Rankin Scale (mRS) | BIIB093 | Score: 2 | 5.1 | percentage of participants | |
| Part 1: Percentage of Participants With Improvement in Functional Outcome at Day 90 Assessed Via the Modified Rankin Scale (mRS) | Placebo | Score: 3 | 12.6 | percentage of participants | |
| Part 1: Percentage of Participants With Improvement in Functional Outcome at Day 90 Assessed Via the Modified Rankin Scale (mRS) | BIIB093 | Score: 3 | 12.0 | percentage of participants | |
| Part 1: Percentage of Participants With Improvement in Functional Outcome at Day 90 Assessed Via the Modified Rankin Scale (mRS) | Placebo | Score: 4 | 25.2 | percentage of participants | |
| Part 1: Percentage of Participants With Improvement in Functional Outcome at Day 90 Assessed Via the Modified Rankin Scale (mRS) | BIIB093 | Score: 4 | 23.5 | percentage of participants | |
| Part 1: Percentage of Participants With Improvement in Functional Outcome at Day 90 Assessed Via the Modified Rankin Scale (mRS) | Placebo | Score: 5/6 | 57.9 | percentage of participants | |
| Part 1: Percentage of Participants With Improvement in Functional Outcome at Day 90 Assessed Via the Modified Rankin Scale (mRS) | BIIB093 | Score: 5/6 | 56.2 | percentage of participants | |
| Part 1: Time to All-Cause Death Through Day 90 | Placebo | NA | Inter-Quartile Range 37 to NA | days | |
| Part 1: Time to All-Cause Death Through Day 90 | BIIB093 | NA | Inter-Quartile Range 18 to NA | days | |
| Part 1: Percentage of Participants Who Achieved mRS 0-4 at Day 90 | Placebo | 41.6 | percentage of participants | ||
| Part 1: Percentage of Participants Who Achieved mRS 0-4 at Day 90 | BIIB093 | 42.9 | percentage of participants | ||
| Part 1: Midline Shift at 72 Hours as Assessed by Non-contrast Computed Tomography (NCCT) or Magnetic Resonance Imaging (MRI) | Placebo | 6.32 | Standard Deviation 4.760 | millimeters (mm) | |
| Part 1: Midline Shift at 72 Hours as Assessed by Non-contrast Computed Tomography (NCCT) or Magnetic Resonance Imaging (MRI) | BIIB093 | 7.02 | Standard Deviation 4.565 | millimeters (mm) | |
| Part 1: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Placebo | AEs | 95.4 | percentage of participants | |
| Part 1: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | BIIB093 | AEs | 97.3 | percentage of participants | |
| Part 1: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | Placebo | SAEs | 68.3 | percentage of participants | |
| Part 1: Percentage of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) | BIIB093 | SAEs | 76.8 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02864953/results